SimInSitu

• Home
• Project
  • Objectives
  • Ambition
  • Workplan
• Partners
• Newsletter
• Contact

• Home
• Project
  • Objectives
  • Ambition
  • Workplan
• Partners
• Newsletter
• Contact

In-silico Development- and Clinical-Trial-Platform for Testing in-situ Tissue Engineered Heart Valves

- SimInSitu -

Research Goal

SimInSitu is aiming to develop a sophisticated in-silico method to predict the short- and long-term behavior of in-situ tissue engineered heart valves (TEHV) by combing advanced tissue remodeling algorithms with a personalized virtual heart modelling approach. The method will be specifically developed to predict the complex transformation process of biodegradable heart valves from the initially synthetic scaffold into a fully remodeled & functional valve.

Though, significant progress was made during the past years in developing TEHV based devices, it remains very challenging, costly, time-consuming, and rich with obstacles. New knowledge can only be generated through a tedious trial & error process (requiring preclinical and clinical studies), since the restorative process cannot be replicated in an in-vitro environment.

Advanced Computer Modelling & Simulation technologies have the potential to overcome this limitation by allowing to test new designs, modified scaffold compositions, or other applications in a virtual patient-specific environment – in-silico. The availability of this computer model could contribute significantly to an acceleration of especially the ETR-device development and accelerate their translation into the clinic and market.

Objectives

Ambition

Workplan

SimInSitu aims to develop a validated in-silico method capable of predicting short- and long-term safety & performance of in-situ tissue engineered heart valve

Support the development of in-situ tissue-engineered heart valve devices by generating beyond state-of-the-art simulation capabilities:

• Digital-Twin technology to investigate the device behaviour in a virtual patient-specific environment
• apply hierarchical V&V / UQ methodology to establish credibility evidence 
• incorporate advanced tissue-remodelling and growth algorithms to account for the ETR process.

SimInSitu will follow a traditional phase-based development plan, which will start with various initially independent work-packages and will converge towards the development of the in-silico platform. Each phase and work-package will have its own deliverables and milestones.

Newsletter

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 101017523

SimInSitu